Adjuvant colon cancer chemotherapy: where we are and where we'll go

被引：70

作者：

Lombardi, L. ^{[1
]}

Morelli, F. ^{[1
]}

Cinieri, S. ^{[2
]}

Santini, D. ^{[3
]}

Silvestris, N. ^{[4
]}

Fazio, N. ^{[5
]}

Orlando, L. ^{[2
]}

Tonini, G. ^{[3
]}

Colucci, G. ^{[4
]}

Maiello, E. ^{[1
]}

机构：

[1] IRCCS Casa Sollievo Sofferenza, Med Oncol Unit, I-71013 San Giovanni Rotondo, FG, Italy

[2] Hosp Perrino, Med Oncol Unit, Brindisi, Italy

[3] Univ Campus Biomed, Med Oncol Unit, Rome, Italy

[4] Canc Inst Giovanni Paolo II, Med & Expt Oncol Unit, Bari, Italy

[5] Ist Europeo Oncol, Med Oncol Unit, Milan, Italy

来源：

CANCER TREATMENT REVIEWS | 2010年 / 36卷

关键词：

Adjuvant chemotherapy; Colon cancer; Trial; Molecular markers; DISEASE-FREE SURVIVAL; MICROSATELLITE-INSTABILITY STATUS; STAGE-II; COLORECTAL-CANCER; MISMATCH-REPAIR; PLUS LEUCOVORIN; FLUOROURACIL; THERAPY; OXALIPLATIN; IRINOTECAN;

D O I：

10.1016/S0305-7372(10)70018-9

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Many patients with early-stage colon cancer are cured with surgery alone, even if the standard of care remains an uniform approach to adjuvant chemotherapy based primarily on tumour stage. Consequently, it is important to individualize decision-making in this subset of patients with the aim to identify potential prognostic and predictive markers in colon cancer. While 5-fluorouracil, leucovorin, and oxaliplatin are widely known as gold treatment in the post-operative of stage III, well-validated molecular markers might help define which patients with stage II disease are likely to benefit from adjuvant therapy as well. Herein we review the use of adjuvant chemotherapy in colon cancer and analyzed the date on the clinical development of molecular markers to individualize another therapeutic approach in colon cancer. (C) 2010 Elsevier Ltd. All rights reserved.

引用

页码：S34 / S41

页数：8

共 50 条

[21] LOUISIANA - WHERE WE ARE AND WHERE WE HOPE TO GO
DURBIN, GJ
SUGAR JOURNAL, 1978, 40 (10): : 8 - 8
[22] GRAVITATIONAL WAVES: WHERE WE ARE, WHERE WE GO
Ricci, Fulvio
7TH ROMA INTERNATIONAL CONFERENCE ON ASTROPARTICLE PHYSICS (RICAP18), 2019, 209
[23] Synucleinopathies: Where we are and where we need to go
Bras, Ines Caldeira
Dominguez-Meijide, Antonio
Gerhardt, Ellen
Koss, David
Lazaro, Diana F.
Santos, Patricia, I
Vasili, Eftychia
Xylaki, Mary
Outeiro, Tiago Fleming
JOURNAL OF NEUROCHEMISTRY, 2020, 153 (04) : 433 - 454
[24] Organoids, Where We Stand and Where We Go
Don, Flaminia Kaluthantrige
Huch, Meritxell
TRENDS IN MOLECULAR MEDICINE, 2021, 27 (05) : 416 - 418
[25] Updates of Adjuvant Therapy in Pancreatic Cancer: Where Are We and Where Are We Going?
Li, Jia
Merl, Man Yee
Chabot, John
Saif, Muhammad Wasif
JOURNAL OF THE PANCREAS, 2010, 11 (04): : 310 - 312
[26] Anticoagulation: where we are and where we need to go
Geoffrey D. Barnes
James B. Froehlich
Journal of Thrombosis and Thrombolysis, 2009, 28
[27] LASERS: Where we began, where we have gone, where we are now. Where will we go?
Reinisch, Lou
LASERS IN SURGERY AND MEDICINE, 2023, 55 (10) : 861 - 861
[28] Immunoteratology: Where we are and where to go
Toder, V
Torchinsky, A
AMERICAN JOURNAL OF REPRODUCTIVE IMMUNOLOGY, 1996, 35 (02): : 114 - 117
[29] Breast Cancer-Associated Fibroblasts: Where We Are and Where We Need to Go
Buchsbaum, Rachel J.
Oh, Sun Young
CANCERS, 2016, 8 (02)
[30] Medical robotics: where we come from, where we are and where we could go
Troccaz, Jocelyne
INDUSTRIAL ROBOT-AN INTERNATIONAL JOURNAL, 2008, 35 (04) : 289 - 289

← 1 2 3 4 5 →